3627 results for «2670»
3627 results
If I can’t stent it, should I care? Unmasking hidden atherosclerosis through novel imaging techniques
22 May 2025 – From EuroPCR 2025
Unveil the potential of novel imaging techniques in identifying hidden atherosclerosis and silent inflammation. This session discusses the role of perivascular adipose tissue in plaque development, highlights advances in early inflammation detection, and explores clinical management of patients with athero-inflammation beyond traditional stenting options.
Challenges and solutions in an expanding TAVI world
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session addresses key challenges and emerging solutions in today’s rapidly evolving TAVI landscape. It presents the latest evidence on valve replacement in low-risk patients with aortic stenosis, alongside strategies for navigating the complexities of lifetime management in TAVI candidates. The programme features a...
China experience in TAVI evolution
22 May 2025 – From EuroPCR 2025
This session highlights key innovations and recent research from China in the field of transcatheter aortic valve implantation (TAVI). Leading cardiovascular specialist present new data on pacing strategies, comparing left bundle branch area pacing with traditional right ventricular pacing in TAVI patients. They also explore the use...
Mitral and tricuspid hotline: long-term outcomes
20 May 2025 – From EuroPCR 2025
Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.
Align for the future with next gen Myval transcatheter heart valve series
16 Nov 2025 – From PCR London Valves 2025
This session delivers an in-depth update on the next generation Myval transcatheter heart valve (THV) series, covering clinical evidence, optimal implantation strategies, and forthcoming innovations. Attendees will examine operator strategies, interactive CT analyses, live procedural demonstrations, and real-world data, providing a comprehensive perspective on advancing TAVI...
Day case TAVI - The future standard of care for most TAVI patients
16 Nov 2025 – From PCR London Valves 2025
Examining the UK experience, this session discusses the emerging standard of day case TAVI and its potential application across Europe. It evaluates patient-centered risks and benefits, operational requirements, and the evolving role of clinical valve coordinators to facilitate safe and efficient day case pathways for TAVI...
From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients
16 Nov 2025 – From PCR London Valves 2025
This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...
How to optimise TAVI outcomes in extreme patient anatomies?
16 Nov 2025 – From PCR London Valves 2025
Focused on optimizing TAVI outcomes in patients with challenging anatomies, this session addresses strategies for small and large annular sizes, as well as lifetime management considerations for younger patients. Case presentations and implant strategy discussions provide practical guidance for achieving optimal procedural results in extreme patient...
A simple low profile solution to the pulmonary embolism problem: EKOS
21 May 2025 – From EuroPCR 2025
Discover a streamlined approach to pulmonary embolism treatment in this EuroPCR 2025 session. Learn how ultrasound-assisted thrombolysis improves right ventricular function and pulmonary perfusion while enabling timely reperfusion with low-dose thrombolytic therapy delivered directly to the clot. Explore the latest data from the HI-PEITHO randomised trial...
Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support: new evidence and insights
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a comprehensive update on cardiogenic shock and high-risk PCI, featuring expert analysis of the DanGer-SHOCK and ECLS-SHOCK trials, new insights one year after DanGer-SHOCK, and practical considerations for managing PCI in patients with severely reduced LVEF. Expect to gain a deeper...
Broadening OPTIONs for LAA closure: innovations and outcomes
20 May 2025 – From EuroPCR 2025
Explore the latest insights into LAA closure from EuroPCR 2025. This session highlights results from the OPTION trial—the largest RCT comparing LAAC (with Watchman FLX) to DOAC therapy in AF patients undergoing ablation. The findings? Comparable stroke prevention at 3 years, with a 56 % reduction...
TAVI in bicuspid aortic valve disease
22 May 2025 – From EuroPCR 2025
Explore the unique challenges of TAVI in bicuspid aortic valve disease with a focus on long-term outcomes, residual gradients, prosthesis-patient mismatch, and anatomical subtype comparisons. This session draws on international registry data to inform clinical decision-making and optimize procedural strategies in this complex patient population.
Coronary physiology: FFR and beyond
22 May 2025 – From EuroPCR 2025
Advance your understanding of coronary physiology with a focus on fractional flow reserve (FFR) and beyond. This session covers randomized trials comparing physiology-guided treatment to standard care in ANOCA, graft patency related to quantitative flow ratio, impacts of microvascular dysfunction on patient outcomes, and prognostic value...
Advanced tools for the diagnosis of coronary artery disease
22 May 2025 – From EuroPCR 2025
This session highlights advanced diagnostic tools for coronary artery disease, focusing on innovative pressure gradient assessments, computed tomography perfusion accuracy in stented patients, head-to-head comparisons of IQ-FFR with invasive FFR, and comprehensive evaluations of coronary physiology and plaque vulnerability derived from angiography.
Redefining the red flags: early detection of myocardial infarction in women
22 May 2025 – From EuroPCR 2025
Gain a unique patient-centered perspective on early myocardial infarction detection in women. This session features a survivor's story, collaborative step-by-step clinical approaches, and key aspects of cardiac rehabilitation, emphasizing shared decision-making to improve patient outcomes in complex cases.
TAVI in difficult scenarios: bicuspid anatomy and pure aortic regurgitation
22 May 2025 – From EuroPCR 2025
Address challenging TAVI scenarios involving bicuspid anatomy and pure aortic regurgitation with insights from international experiences. This session compares treatment options in China and Germany, explores anatomical and disease differences, and reviews various TAVI devices through detailed case presentations and expert commentary.
Antiplatelet strategies for patients undergoing PCI
22 May 2025 – From EuroPCR 2025
Delve into this comprehensive session focusing on antiplatelet strategies for patients undergoing PCI. Explore evidence and clinical insights on ticagrelor monotherapy post-AMI stenting, shortened dual antiplatelet therapy (DAPT) durations, the role of CYP2C19 genotyping in stent thrombosis risk, the effectiveness of dual antithrombotic therapy in atrial...
Radiation protection: the good and the bad
22 May 2025 – From EuroPCR 2025
This session provides essential guidance on radiation protection in the cath lab. Learn practical steps to minimize radiation exposure for yourself and your team, manage the ergonomic challenges of protective gear, and develop skills to foster a culture of radiation safety within your workplace. Understand the...
Managing ischaemic and bleeding risk of NSTEMI patients
22 May 2025 – From EuroPCR 2025
Gain valuable insights into managing ischemic and bleeding risks in NSTEMI patients. This session reviews optimal timing for invasive strategies, variability in care processes, radial access approaches, and innovative antithrombotic strategies such as aspirin omission and prasugrel monotherapy to minimize bleeding while optimizing outcomes.
Catheter-directed therapy for intermediate-high-risk and high-risk pulmonary embolism; where do we stand?
22 May 2025 – From EuroPCR 2025
Explore the evolving landscape of catheter-directed therapy for intermediate-high and high-risk pulmonary embolism. This session covers patient selection criteria, clinical signs indicating the need for intervention, management of potential complications, and ongoing studies shaping future treatments. Case-based discussions illustrate practical applications and key learnings.
